
Palbociclib Combination Prolongs Life After Breast Cancer Hormone Therapy
MUNICH—Patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer who were treated with a combination of the cyclin dependent kina
MUNICH—Patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer who were treated with a combination of the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib in combination with fulvestrantlived longer than those receiving a placebo with fulvestrant in the prospective, randomized, double-blind, phase three PALOMA-3 study from which overall survival (OS) data were reported at the 2018 annual congress of the European Society for Medical Oncology, ESMO.
http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=LBA2_PR
New standard
“This combination should be the standard of care for patients progressing on endocrine therapy,” said PALOMA-3 study senior investigator Massimo Cristofanilli MD FACP, Professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University in Chicago IL. He tells the Audio Journal of Oncology: “There’s no doubt there is a clinical and meaningful strong benefit—not only in delaying the disease but also [in] survival. This should replace the use of chemotherapy,” he said.
The trial found that patients taking the CDK4/6 inhibitor with fulvestrant lived a median of 6.9 months longer than those in the control group treated with placebo and fulvestrant.
Tags
Next in ESMO 2018
All 11 interviewsInterview 10 of 11

Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer
MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSC
Related Episodes

Xichun Hu MD PhD; ESMO 2025: Antibody Drug Conjugate Trastuzumab Botidotin Outperforms Trastuzumab Emtansine in Patients with HER2-Positive Unresectable or Metastatic Breast Cancer
A Chinese ADC and a western ADC slugged it out at the 2025 ESMO held in Berlin.

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer
MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after first line chemo-immunotherapy induction. Results from the phase 3 DeLLphi-305 trial were reported at the 2026 Annual Congress of the European Society for Medical Oncology showing significantly improved overall and progression-free survival. Peter Goodwin spoke with study author Jacob Sands MD, Associate Chief of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in Boston, USA, and Assistant Professor of Medicine at Harvard Medical School:

Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer
MADRID, Spain—The antibody-drug conjugate datopotamab deruxtecan (aTrop-2-directed antibody carrying a topoisomerase inhibitor payload) achieved clinically meaningful intracranial responses among patients with resected inoperable or metastatic triple negative breast cancer with CNS involvement in the TROPION-Breast02 study discussed at the 2026 Annual Meeting of the European Society for Medical Oncology. Peter Goodwin heard the details from the study’s first author: Rebecca Dent MD, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre in Singapore.